Last updated on October 2013

ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children With Refractory, Relapsed or Progressive Neuroblastoma


Brief description of study

ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children With Refractory, Relapsed or Progressive Neuroblastoma

Detailed Study Description

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01767194?term=ANBL1221&rank=1

Clinical Study Identifier: TX137243

Contact Investigators or Research Sites near you

Start Over

Patricia Green

Memorial University Medical Center
Savannah, GA USA
  Connect »